Health Care Cost Implications of Sildenafil Citrate
Author:
- 1 September 2004
- journal article
- review article
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 1 (2) , 141-149
Abstract
As prescription drug expenditures increase, third-party payors are increasingly scrutinizing costs and reimbursement guidelines, such as for medications that treat chronic conditions that are not necessarily directly life threatening (i.e., obesity, nicotine addiction, and erectile dysfunction). To review the costs and consequences of pharmacy benefit reimbursement policies related to erectile dysfunction therapies, using sildenafil citrate as the case study. Data and references were found through searches of PubMed and Google. To meet the varied health needs of a defined population under reasonable resource constraints requires analysis of cost and of the economic and non-economic consequences of a treatment. Based on analysis of sildenafil data, oral therapy of erectile dysfunction provides substantial cost savings when compared with other treatment options and contributes insignificant overall costs to health plans. Regardless, health plans impose controls to limit reimbursement. Because erectile dysfunction is often a precursor to other conditions, such limitations could compromise detection and management of underlying disease (e.g., depressive, cardiovascular, and urogenital). Reimbursement restrictions may also decrease membership satisfaction and re-enrollment rates.Keywords
Funding Information
- Pfizer Inc
This publication has 35 references indexed in Scilit:
- The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and SpendingNew England Journal of Medicine, 2003
- Approaches to pharmacy benefit management and the impact of consumer cost sharingClinical Therapeutics, 2003
- Large Employers' New Strategies in Health CareNew England Journal of Medicine, 2002
- Job-Based Health Benefits In 2002: Some Important TrendsHealth Affairs, 2002
- In search of “non-disease”BMJ, 2002
- Inflation Spurs Health Spending In 2000Health Affairs, 2002
- Drug Coverage Decisions: The Role Of Dollars And ValuesHealth Affairs, 2000
- Explaining Drug Spending Trends: Does Perception Match Reality?Health Affairs, 2000
- Making Insurance Coverage for New Technologies Reasonable and AccountableJAMA, 1998
- ImpotenceJAMA, 1993